Jim Cramer Calls Medtronic (MDT) a “Quandary” as Growth Surges and Diabetes Exit Nears
At a glance
- $MDT today+0.02%last $102.88
- Vs industry peers+2.64 pts6-peer median −2.62% · far ahead
- Since Sep 10+12.3%from the first trade after the story
- 52-week range3.2% below high$73.31 – $106.33
- Last reported profit$1.47Bquarter to Jul 31, 2026 · 10-Q
- Next upIn 8 days$MDT earnings
- Key person: Filed with SEC
- Clear: legal, regulatory, security, operational, financial integrity
Options price an average move of ±7.0% by Dec 18 — the at-the-money straddle, the typical size of the move; the bands are one standard deviation.
Early signals (1) — filed with the SEC or first reported, not yet widely covered
- Key person · SEC 8-K, Item 5.02, Oct 19: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: Approvals and strong trial data can reprice a drugmaker quickly — especially when one product is most of the company.
- How the stock is trading: $MDT +0.02% in the latest session.
- Timing: It was published before the opening bell, so the next session was the first chance to trade on it.
Where the stock stands
Medtronic plc. ($MDT) edged up 0.02% to $102.88 in the latest session. Over the past month it is up 10.9%. That leaves it 3.2% below its 52-week high of $106.33 and 40% above its low of $73.31. Its range over the year spans 45%, which is moderate.
What the filings say
In its latest report (10-Q, filed Sep 3, 2026), $MDT earned $1.47B over the quarter to Jul 31, 2026 on revenue of $9.76B. Operations brought in $1.79B of cash over the quarter to Jul 31, 2026; after capital spending, free cash flow was $1.29B. Total liabilities were $42.46B against $1.69B of cash on Jul 31, 2026. Its most recent filings before this story: 10-Q on Sep 3, 2026, 8-K on Sep 1, 2026, 10-K on Jun 18, 2026. Figures are as filed with the SEC; the $MDT page has the full statements.
How much coverage it is getting
Nothing new on Medtronic plc. has come through Wook's feeds in the last 30 days, so this is still the most recent story on it.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
Coming up
$MDT earnings in 8 days — on the calendar well before this story broke. Fresh numbers are close.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $MDT page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. Wook AI, at the top of the page, can work out how far $MDT is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Yahoo Finance published this on September 10, 2026. $MDT has moved +12.29% ($91.62 to $102.88). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
